Nephrol Dial Transplant (2000) 15: 2014-2019
© 2000 European Renal Association-European Dialysis and Transplant Association
The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin ß: results from a randomized controlled multicentre trial
on behalf of the Swedish Study Group
1 Department of Nephrology, Centralsjukhuset, Karlstad, 2 Department of Nephrology, Karolinska Hospital, Stockholm, 3 Dialysis unit, Sophiahemmet Hospital, Stockholm, 4 Department of Medicine, Länssjukhuset Ryhov, Jönköping, 5 Department of Nephrology, Universitetssjukhuset, Lund, 6 Clinical Study Service AB, Box 410, S-681/28 Kristinehamn, Sweden
Background. Anaemia in haemodialysis patients can be effectively treated with erythropoietin. We investigated whether subcutaneous (SC) epoetin ß administered once weekly was as effective as the same weekly dosage given in two to three divided doses.
Methods. One hundred and fifty-eight patients (delivered Kt/V >1.0, where K=dialyser-renal urea clearance, t=dialysis time and V=filtration volume, obtained by urea kinetic modelling) were randomized to treatment with SC epoetin ß either once weekly (n=118), or to their original dosage two or three times weekly (control group, n=40) for 24 weeks. All patients received intravenous iron supplementation when necessary.
Results. Eight-eight patients in the once weekly group and 30 patients in the control group were treated for at least 16 weeks and are included in the analysis. Stable haemoglobin levels were maintained without epoetin dose increases in 73% of patients in both groups. Mean haemoglobin levels at randomization and after 16 and 24 weeks were 11.4, 11.1 and 11.1 g/dl, respectively, in the once weekly group compared with 11.2, 11.3 and 11.2 g/dl, respectively, in the control group. The mean weekly epoetin ß dosages at randomization and after 16 and 24 weeks were 102, 103 and 106 IU/kg bodyweight, respectively, in the once weekly group compared with 109, 109 and 115 IU/kg bodyweight, respectively, in the control group. No statistically significant between-group differences were apparent for changes in haemoglobin levels or epoetin ß dosages at week 24.
Conclusions. Once weekly SC administration of epoetin ß is as safe and effective in maintaining haemoglobin levels in stable haemodialysis patients as two or three times weekly administration of the same total dose. By using the once weekly regimen, patients can avoid up to 104 injections per year. This would reduce clinic time for patients who do not self administer, and may also encourage self-administration and improve overall compliance.
Keywords: epoetin beta; renal anaemia; subcutaneous
Correspondence and offprint requests to: Lars G. Weiss M. D. PhD, Department of Nephrology, Centralsjukhuset, S-651 85 Karlstad, Sweden
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Robach, S. Recalcati, D. Girelli, C. Gelfi, N. J. Aachmann-Andersen, J. J. Thomsen, A. M. Norgaard, A. Alberghini, N. Campostrini, A. Castagna, et al. Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin Blood, June 25, 2009; 113(26): 6707 - 6715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. K. Lee, S. G. Kim, J. W. Seo, J. E. Oh, J.-W. Yoon, J.-R. Koo, H. J. Kim, and J. W. Noh A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3240 - 3246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Carrera, A. Disney, and M. Molina Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv19 - iv30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Foley Do We Know the Correct Hemoglobin Target for Anemic Patients with Chronic Kidney Disease? Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 678 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Messa, M. A. Nicolini, B. Cesana, B. Brezzi, T. Zattera, A. Magnasco, G. Moroni, and M. Campise Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients Nephrol. Dial. Transplant., February 1, 2006; 21(2): 431 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Grzeszczak, W. Sulowicz, B. Rutkowski, A. F. de Vecchi, R. Scanziani, P.-Y. Durand, A. Bajo, V. Vargemezis, and on behalf of the European Collaborative Group The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin {beta} in peritoneal dialysis patients with chronic renal anaemia Nephrol. Dial. Transplant., May 1, 2005; 20(5): 936 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Tolman, D. Richardson, C. Bartlett, and E. Will Structured Conversion from Thrice Weekly to Weekly Erythropoietic Regimens Using a Computerized Decision-Support System: A Randomized Clinical Study J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1463 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Weiss Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1330 - 1331. [Full Text] [PDF]
|
|
|
|
|
|
I. C. Macdougall Reply Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1331 - 1331. [Full Text] [PDF]
|
|
|
|
|
|
R. Brunkhorst, J. Bommer, J. Braun, M. Haag-Weber, C. Gill, J. Wagner, and T. Wagener Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1224 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Macdougall, J. Matcham, and S. J. Gray Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis Nephrol. Dial. Transplant., March 1, 2003; 18(3): 576 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Macdougall Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2047 - 2051. [Full Text] [PDF]
|
|
|
|
|
|
C. H. Jones, L. Ridley, D. Richardson, and L. Weiss Which EPO dose per week? Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1855 - 1855. [Full Text] [PDF]
|
|
|
|
|
|
S. Andrulli, M. D'Amico, F. Locatelli, and L. G. Weiss Is the use of subcutaneous epoetin {beta} once a week really equivalent to a more frequent administration of the same total dose? Nephrol. Dial. Transplant., December 1, 2001; 16(12): 2439 - 2440. [Full Text] [PDF]
|
|
|
|
|
|
K.-U. Eckardt After 15 years of success--perspectives of erythropoietin therapy Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1745 - 1749. [Full Text] [PDF]
|
|